Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: The BayWatcher who wrote (246)	2/27/1998 2:14:00 AM
From: David S.	Read Replies (1) \| Respond to of 384

sonus current market cap still greatly exceeds that of MB. The safety profile of the mb product blows away that of the sonus product. size of the market for applications of the sonus product outside of the heart is basically a pipe-dream. safety problems in clinicals are the result of poor and I might add, unusual experimental protocol - they had problems early on with the product, and the formulation has been changed mid stream - more than once. In effect, data on the product Sonus wants to bring to market is sketchy because the product they put through phase 1 was changed, and in fact my recollection is that they actually changed the product during final clinical trials. Their follow on product is NOT a big deal - it was developed as a result of Sonus needing to change current formulation. note the word needing in the previous sentence. Sonus mislead the FDA & that's not usually a good idea.